RadMD Reaches 150th Clinical Trial

Trained and Certified Blinded Readers Help ICON Medical Imaging Complete
Oncology Trial Ahead of Schedule

DOYLESTOWN, Penn., Oct. 5 /PRNewswire/ -- Completing a major milestone in its
three years of operation, RadMD LLC (www.rad-md.net) announced that it has
sourced readers for 150 clinical trials.

The most recent trial, conducted by ICON Medical Imaging for a leading
pharmaceutical company, was designed to test the efficacy of a new treatment
for metastatic kidney cancer. The trial used medical imaging to support the
primary analysis of Progression Free Survival based on an independent central
radiological review.

"The results of the reads showed that the drug delayed tumor growth by five
months, with patients living twice as long without tumor growth as other
cancer victims in the study's control arm. Ultimately, this provided the FDA
with the information it needed to approve the drug," said Ted Gastineau,
president and co-founder, ICON Medical Imaging. "Quality reads are critical
and delays cost money and keep drugs from getting to the people who need it
most. We are confident that RadMD's blinded readers have the skills and
experience necessary to help us support our clients through the drug
development process."

RadMD sourced five radiologists with a specialty in oncology within one week
of the request and helped with resources and scheduling - allowing completion
of the analysis ahead of schedule. Each radiologist received formalized
training and extensive testing on a variety of topics related to the use of
medical imaging in clinical trials from the company's Blinded Reader and
Investigator Training Institute (BRITI)(TM). All CT scans, MRIs and bone scans
obtained at baseline during the treatment period and the follow-up period were
sent to the independent imaging core lab at ICON Medical Imaging.

Founded by medical imaging experts Kohkan Shamsi, MD, PhD, and Richard Patt,
MD, RadMD sources clinical experts and provides consulting services for
pharmaceutical, biotech and medical device trials and offers both
CME-certified and non-CME courses on medical imaging in clinical trials for
both on-site and offsite readers. The company's database of 600 readers come
from multiple specialties including radiologists, pathologists, oncologists,
cardiologists, medical physicists, medical technologists and others. RadMD has
sourced readers for trials in cardiovascular, oncology, neurology,
musculoskeletal, endocrinology and sports medicine.

"CRO's and pharmaceutical companies usually manage many concurrent trials and
the availability of quality blinded readers saves money, decreases variability
and expedites the trial process," said Dr. Shamsi. "By facilitating a key
component of the clinical trial process, RadMD helps pharmaceutical, biotech
and medical device companies reduce clinical development time, thus getting
important anti-cancer and other treatments to the market more quickly."

For more information about RadMD, please visit www.rad-md.net or call
267-247-5544 ext. 500.

About RadMD

RadMD LLC (www.rad-md.net) provides consulting, training, and blinded reader
services to the pharmaceutical and biotech industry. Services include defining
and developing imaging strategies in clinical development programs, education
and training through BRITI (the Blinded Reader & Investigator Training
Institute), and the sourcing and management of blinded readers for clinical
trials.

BRITI is a trademark of RadMD LLC.

This release, and additional RadMD resources, is available online in the
Feintuch Communications media room at www.feintuchcommunications.com.

Contact:
Pablo Andreu / Steph Johnson
Feintuch Communications
212.808.4903 / 212.808.4904
pablo@feintuchpr.com / steph@feintuchpr.com

SOURCE RadMD LLC

Pablo Andreu, +1-212-808-4903, pablo@feintuchpr.com, or Steph Johnson,
+1-212-808-4904, steph@feintuchpr.com, both of Feintuch Communications, for
RadMD LLC